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Abstract: Chronic kidney disease (CKD) is associated with an increased cardiovascular risk in a 
broad spectrum of populations. However, the risk associated with a reduced estimated glomerular 
filtration rate (eGFR) in patients with stable coronary artery disease receiving standard care in the 
modern era, independently of baseline cardiovascular disease, risk factors, and comorbidities, 
remains unclear. We analyzed data from 21,911 patients with stable coronary artery disease, 
enrolled in 45 countries between November 2009 and July 2010 in the CLARIFY registry. Patients 
with abnormal renal function were older, with more comorbidities, and received slightly 
lower—although overall high—rates of evidence-based secondary prevention therapies than 
patients with normal renal function. The event rate of patients with CKD stage 3b or more (eGFR 
<45 mL/min/1.73 m2) was much higher than that associated with any comorbid condition. In a 
multivariable adjusted Cox proportional hazards model, lower eGFR was independently 
associated with a graded increased risk of cardiovascular mortality, with adjusted HRs (95% CI) of 
0.98 (0.81–1.18), 1.31 (1.05–1.63), 1.77 (1.38–2.27), and 3.12 (2.25–4.33) for eGFR 60–89, 45–59, 30–44, 
and <30 mL/min/1.73 m2, compared with eGFR ≥90 mL/min/1.73 m2. A strong graded independent 
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relationship exists between the degree of CKD and cardiovascular mortality in this large cohort of 
patients with chronic coronary artery disease, despite high rates of secondary prevention therapies. 
Among clinical risk factors and comorbid conditions, CKD stage 3b or more is associated with the 
highest cardiovascular mortality. 
Keywords: chronic kidney disease; chronic coronary artery disease; CLARIFY registry 
 
1. Introduction 
Chronic kidney disease (CKD) is a well-recognized risk factor for mortality and cardiovascular 
disease. This increased risk has been noted in general population cohorts [1–5], in cohorts at high 
risk for, or with established, cardiovascular disease [4,6] and in patients with heart failure [7]. 
However, few data are available in the specific population of patients with stable coronary artery 
disease, especially in a contemporary cohort including patients largely treated with drugs associated 
with prognostic benefit [8] and without severe heart failure at inclusion. 
We used data from the global prospective observational longitudinal registry of patients with 
chronic coronary artery disease (CLARIFY) to compare the risk associated with different stages of 
CKD with that associated with other risk factors and comorbid conditions. In addition, we assessed 
whether reduced renal function is a risk factor, independent of other established risk factors and 
comorbidities, in patients with chronic coronary artery disease treated according to standard care in 
the modern era. 
2. Methods 
2.1. Study Design and Participants 
Clarify is an international, prospective, observational, longitudinal registry of outpatients with 
chronic coronary artery disease (ISRCTN43070564; www.clarifyregistry.com). The study rationale 
and methods have been published elsewhere [9,10]. Briefly; 32,703 patients were enrolled in 45 
countries in Africa, Asia, Australia, Europe, the Middle East, and North, Central, and South America 
between November 2009 and June 2010. Eligible patients had chronic coronary artery disease proven 
by a history of at least one of the following: Documented myocardial infarction more than three 
months before enrolment; angiographic demonstration of coronary stenosis of more than 50%; chest 
pain with evidence of myocardial ischemia (stress electrocardiogram, stress echocardiograph, or 
myocardial perfusion imaging); or coronary artery bypass graft or percutaneous coronary 
intervention performed more than three months before enrolment. These criteria were not mutually 
exclusive. Exclusion criteria were hospital admission for cardiovascular reasons (including 
revascularization) in the past 3 months; planned revascularization; conditions hampering 
participation over 5-year follow-up, such as limited cooperation, inability to provide informed 
consent, serious non-cardiovascular disease, or conditions interfering with life expectancy (e.g., 
cancer; drug abuse); or other severe cardiovascular diseases such as advanced heart failure, severe 
valve disease, or history of valve repair or replacement. CKD, per se, was not an exclusion criterion. 
To ensure that the study population was representative of chronic coronary artery disease 
outpatients, recruitment of sites and subjects was based on a predefined selection of physicians 
(cardiologists as well as office-based primary care physicians and physicians based in hospitals with 
outpatient clinics) by national coordinators, using the best available epidemiological data in each 
country reflecting the burden of coronary artery disease; this was done in an attempt to provide a 
distribution of physicians across regions and locations (i.e., urban; suburban; or rural areas), 
mimicking the epidemiological patterns in each country. In each practice; patient recruitment was 
restricted over a brief period to achieve near-consecutive patient enrolment in order to avoid 
selection bias. The study was conducted in accordance with the principles in the Declaration of 
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Helsinki and local ethical approval was obtained in all countries prior to recruitment. All patients 
gave written informed consent before any data acquisition was performed. The study was registered 
at ISRCTN as ISRCTN43070564. 
2.2. Data Collection 
The investigators completed standardized case report forms at baseline and at a yearly patient 
visit (plus or minus three months) for up to 5 years. In addition, telephone contact with the patient, a 
designated relative or contact, or their physician was attempted in the 6-month interim between the 
yearly visits. At each yearly visit, symptoms, clinical examination, results of the main recent clinical 
and biological tests, treatment, and clinical outcomes were recorded. Patients were treated according 
to usual clinical practice at each institution, with no specific tests or therapies defined in the study 
protocol. Where applicable, registries could be used to retrieve the vital status. Events were accepted 
as reported by physicians and were not adjudicated. Events were accepted as reported by physicians 
following the detailed requirement of the case reports forms and were not adjudicated. However, to 
ensure data quality, onsite monitoring visits were carried out in 5% of randomly selected centres 
with source verification of all events and of 100% of the collected data, centralized verification of the 
electronic case report forms were performed for completeness, consistency, and accuracy, and 
regular telephone contacts with investigators were done to limit missing data and loss to follow-up. 
Baseline estimated glomerular filtration rate (eGFR) was derived from the creatinine-derived 
chronic kidney disease Epidemiology Collaboration (CKD-EPI) equation [11], and analyzed in five 
categories: <30, 30–44, 45–59, 60–89, and ≥90 mL/min/1.73 m2, the latter being used as reference. 
Analyses were also conducted using eGFR as a continuous variable, with values above 90 
mL/min/1.73 m2 truncated at this threshold. Results were provided per 5 unit decrease in eGFR 
below this threshold and scaled at 90 mL/min/1.73 m2. 
A flow diagram of the study population is shown in eFigure in the Supplement; 325 patients 
had an incomplete 5-year follow-up, 10,407 patients had incomplete sets of variables required to 
calculate eGFR (mainly ethnicity, which local ethics committees did not authorize collecting in 
France and Portugal, and creatinine values), and patients with baseline eGFR below 10 mL/min/1.73 
m2 (n = 60) were excluded, leaving a total of 21,911 patients in the present analysis. 
2.3. Study Outcomes 
Pre-specified outcomes of interest were cardiovascular death (primary outcome), all-cause 
death, myocardial infarction (fatal or not), stroke (fatal or not), and hospital admission for heart 
failure (secondary outcomes). Cardiovascular death was defined as death from myocardial 
infarction or stroke, any sudden death including unobserved and unexpected death (while sleeping) 
unless proven otherwise by autopsy, death ascribed to heart failure, death following cardiac or 
vascular procedure/operation, death due to ruptured aneurysm or pulmonary embolism, death due 
to amputation (except for trauma or malignancy), and death that could not be definitely ascribed to 
non-cardiovascular death. 
2.4. Statistical Analysis 
Continuous variables were presented as mean ± standard deviation or median (interquartile 
range), depending on the distribution of the data; categorical data were presented as count and 
percentage. Comparisons between eGFR categories were performed using one-way ANOVA, or 
Kruskal-Wallis test for continuous variables as appropriate and Chi-Squared tests for categorical 
data. 
Event rates and corresponding 95% confidence intervals (CI) for the primary outcome and each 
of the secondary outcomes were provided per 1000 patient-years, using the date of event or 
censoring date. If multiple events were recorded, the event rate was calculated using the date of first 
event. 
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Cox proportional hazards models were used to assess the association between eGFR, in 
categories or as a continuous variable, and outcomes. In addition to crude hazard ratios (HRs), 
adjusted HRs were estimated after adjustment for potential confounding factors, selected a priori as 
potential confounders, namely age, sex, geographical region, smoking status, diabetes, body-mass 
index, treated hypertension, baseline systolic blood pressure, low-density and high-density 
lipoprotein cholesterol levels, previous myocardial infarction, previous percutaneous coronary 
intervention, previous coronary artery bypass grafting, number of diseased coronary vessels at 
baseline, peripheral artery disease at baseline, previous stroke or transient ischemic attack, previous 
hospital admission for (or symptoms of) heart failure, left ventricular ejection fraction, atrial 
fibrillation or flutter, and baseline drugs (any antiplatelet, statins, angiotensin-converting enzyme 
inhibitors, angiotensin-receptor blockers, and beta-blockers). 
Data were analyzed as recorded without imputation for missing data. Adjustment variables 
were analyzed including a category for missing data to minimize the loss of data in the analysis. 
Interaction between eGFR and diabetes, treated hypertension, and age (< or ≥60 years) were 
tested for the categorical and continuous analyses of eGFR. 
The statistical analysis was done with SAS (version 9.3). 
3. Results 
A total of 21,911 patients with chronic coronary artery disease and available baseline eGFR 
were included in the analysis. Baseline characteristics of the patients, in the total study population 
and by category of baseline eGFR, are reported in Table 1. Mean age was 63.9 ± 10.4 years, 16,941 
(77%) were men, 15,731 (72%) had treated hypertension, 6646 (30%) had diabetes, and 2788 (13%) 
and 10,261 (47%) were current and former smokers, respectively. Mean eGFR was 76 ± 19 
mL/min/1.73 m2. 
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Table 1. Demographic and baseline characteristics of the patients, for the total population (n = 21,911) and by estimated glomerular filtration rate (eGFR) subgroup. 
Parameter Number of Patients 
Total Population 
GFR Subgroups (in mL/min/1.73 m2) 
p-Value <30 30–44 45–60 60–89 ≥90 
(n = 21,911) (n = 233) (n = 1166) (n = 3347) (n = 11,693) (n = 5472) 
Age (years) 21,911 63.9 (10.4) 73.1 (9.5) 71.9 (9.0) 69.84 (8.7) 64.7 (9.5) 56.5 (8.8) <0.0001 
Men 21,911 16,941 (77.3) 141 (60.5) 735 (63.0) 2254 (67.3) 9223 (78.9) 4588 (83.9) <0.0001 
Body Mass Index (kg/m2) 21,897 27.5 [24.9, 30.5] 27.2 [24.2, 30.8] 27.6 [24.8, 30.9] 27.5 [24.9, 30.6] 27.4 [25, 30.4] 27.5 [24.9, 30.8] 0.2438 
Diabetes 21,909 6646 (30.3) 131 (56.2) 521 (44.7) 1143 (34.2) 3231 (27.6) 1620 (29.6) <0.0001 
Smoking status 21,911         
Current - 2788 (12.7) 14 (6.0) 69 (5.9) 248 (7.4) 1431 (12.2) 1026 (18.8) <0.0001 
Former - 10,261 (46.8) 112 (48.1) 508 (43.6) 1486 (44.4) 5612 (48.0) 2543 (46.5) - 
Never - 8862 (40.4) 107 (45.9) 589 (50.5) 1613 (48.2) 4650 (39.8) 1903 (34.8) - 
Treated hypertension 21,910 15,731 (71.8) 211 (90.6) 984 (84.4) 2621 (78.3) 8332 (71.26) 3583 (65.5) <0.0001 
Systolic blood pressure (mm Hg) 21,908 131 (17) 133 (20) 133 (18) 133 (18) 131 (17) 129 (16) <0.0001 
Diastolic blood pressure (mm Hg) 21,908 77 (10) 74 (12) 76 (11) 77 (10) 77 (10) 78 (10) <0.0001 
Heart Rate (beats/minute) 21,910 69 (11) 70 (12.3) 69 (12) 69 (11) 68 (11) 69 (11) <0.0001 
Myocardial Infarction 21,911 13,550 (61.8) 136 (58.4) 735 (63.0) 1987 (59.4) 7187 (61.5) 3505 (64.05) 0.0001 
Percutaneous coronary intervention 21,911 12,389 (56.5) 108 (46.34) 579 (49.7) 1700 (50.8) 6549 (56.0) 3453 (63.1) <0.0001 
Coronary artery bypass graft surgery 21,911 5298 (24.2) 89 (38.2) 328 (28.1) 967 (28.9) 2880 (24.6) 1034 (18.9) <0.0001 
Peripheral artery disease 21,909 2095 (9.6) 44 (18.9) 180 (15.4) 418 (12.5) 1065 (9.1) 388 (7.1) <0.0001 
Transient Ischemic Attack 21,910 679 (3.1) 10 (4.3) 75 (6.4) 176 (5.3) 306 (2.6) 112 (2.05) <0.0001 
Stroke 21,910 940 (4.3) 26 (11.2) 105 (9.0) 202 (6.0) 481 (4.1) 126 (2.3) <0.0001 
Atrial fibrillation/Flutter 21,911 1582 (7.2) 34 (14.6) 157 (13.5) 379 (11.3) 831 (7.1) 181 (3.3) <0.0001 
Hospitalization for heart failure 21,911 1104 (5.00) 48 (20.6) 143 (12.3) 236 (7.1) 504 (4.3) 173 (3.2) <0.0001 
Symptoms of heart failure 21,911         
None - 18,348 (83.7) 184 (79.0) 915 (78.5) 2700 (80.7) 9861 (84.3) 4688 (85.67) <0.0001 
NYHA Class II - 2969 (13.6) 37 (15.9) 201 (17.2) 514 (15.4) 1557 (13.3) 660 (12.06) - 
NYHA Class III - 594 (2.7) 12 (5.2) 50 (4.3) 133 (4.0) 275 (2.4) 124 (2.27) - 
Left Ventricular Ejection Fraction (%) 15,731 55.6 (11.2) 49.3 (14.6) 52.3 (12.6) 54.8 (11.8) 56.1 (10.9) 56.03 (10.44) <0.0001 
HbA1C (%) 6638 6.84 (1.82) 7.24 (1.67) 7.09 (1.54) 6.92 (2.69) 6.74 (1.6) 6.89 (1.6) <0.0001 
Creatinine (mmol/L) 21,911 0.088 [0.076, 0.101] 0.198 [0.186, 0.226] 0.141 [0.125, 0.156] 0.112 [0.1, 0.122] 0.088 [0.08, 0.097] 0.071 [0.062, 0.079] <0.0001 
eGFR (mL/min/1.73 m2) 21,911 76 (19) 25 (4) 39 (4) 54 (4) 76 (9) 99 (7) - 
Total Cholesterol (mmol/L) 20,843 4.3 [3.6, 5] 4.2 [3.6, 4.9] 4.2 [3.5, 5] 4.3 [3.6, 5.1] 4.3 [3.7, 5] 4.2 [3.6, 5] 0.0027 
HDL-cholesterol (mmol/L) 18,513 1.1 [1.0, 1.4] 1.0 [0.9, 1.3] 1.1 [0.9, 1.3] 1.1 [1.0, 1.4] 1.1 [1.0, 1.4] 1.1 [0.9, 1.3] <0.0001 
LDL-cholesterol (mmol/L) 17,505 2.3 [1.9, 2.9] 2.3 [1.7, 2.9] 2.2 [1.8, 2.8] 2.3 [1.9, 2.9] 2.4 [1.9, 3.0] 2.4 [1.9, 3.0] 0.0024 
Fasting Triglycerides (mmol/L) 19,262 1.4 [1.0, 2.0] 1.6 [1.1, 2.0] 1.5 [1.1, 2.1] 1.5 [1.1, 2.0] 1.4 [1.0, 1.9] 1.4 [1.0, 2.0] <0.0001 
Baseline medication          
Aspirin 21,910 19,560 (89.3) 180 (77.3) 947 (81.2) 2867 (85.7) 10,460 (89.5) 5106 (93.3) <0.0001 
Thienopyridine 21,902 5650 (25.8) 76 (32.6) 302 (25.9) 795 (23.8) 2855 (24.4) 1622 (29.7) <0.0001 
Any antiplatelet agent 21,911 20,895 (95.4) 207 (88.8) 1055 (90.5) 3118 (93.2) 11,166 (95.5) 5349 (97.8) <0.0001 
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Lipid-lowering drugs 21,911 20,470 (93.4) 213 (91.4) 1081 (92.7) 3074 (91.8) 10,938 (93.5) 5164 (94.4) <0.0001 
Beta-Blockers 21,910 16,625 (75.9) 168 (72.1) 893 (76.6) 2512 (75.1) 8766 (75.0) 4286 (78.3) <0.0001 
Calcium antagonists 21,909 5956 (27.2) 96 (41.2) 372 (31.9) 1065 (31.8) 3155 (27.0) 1268 (23.2) <0.0001 
Angiotensin-converting enzyme inhibitors 21,910 11,408 (52.1) 82 (35.2) 534 (45.8) 1692 (50.6) 6125 (52.4) 2975 (54.4) <0.0001 
Angiotensin II receptor antagonists 21,909 5873 (26.8) 90 (38.6) 445 (38.2) 1074 (32.1) 3067 (26.2) 1197 (21.9) <0.0001 
Any renin-angiotensin system blocker 21,910 16,843 (76.9) 164 (70.4) 929 (79.7)  2680 (80.1) 8975 (76.8) 4095 (74.9)  <0.0001 
Diuretics 21,910 6492 (29.6) 156 (67.0) 633 (54.3) 1380 (41.2) 3193 (27.3) 1130 (20.7) <0.0001 
Data are mean (SD), median (IQR), or number (%). Some percentages do not add up to 100 because of rounding. eGFR = Glomerular Filtration Rate estimated from 
the CKD-EPI equation; NYHA = New York Heart Association (NYHA) Functional Classification; HDL-cholesterol = high-density lipoprotein cholesterol; 
LDL-cholesterol = low-density lipoprotein cholesterol. 
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Compared with patients with eGFR ≥ 90 mL/min/1.73 m2, those with a lower eGFR were older, 
more likely to be female, have diabetes and hypertension, and less likely to be current smokers. They 
were less likely to have undergone percutaneous coronary intervention, and more likely to have 
undergone coronary artery bypass grafting. They had a higher prevalence of peripheral artery 
disease, heart failure, previous stroke, and atrial fibrillation or flutter. They were less likely to 
receive antiplatelet agents, lipid lowering drugs, and angiotensin-converting enzyme inhibitors, but 
more likely to receive angiotensin II receptor blockers. The rate of prescription of any 
renin-angiotensin system blocker was lowest (70.4%) in patients with eGFR <30 mL/min/1.73 m2. 
After a median follow-up of 5 years (4.82; 5.10), 1837 patients died (1158 of cardiovascular 
cause), 829 patients had a myocardial infarction (fatal or not), 493 had a stroke (fatal or not), and 1279 
were hospitalized for heart failure. 
The cumulative incidence of cardiovascular death increased with decreasing eGFR (Figure 1). 
 
Figure 1.  Kaplan-Meier plots showing cumulative incidence of cardiovascular death by eGFR 
category. 
Compared to major risk factors for coronary artery disease and prior cardiovascular history 
(such as previous myocardial infarction or heart failure), CKD stage 3b or more was, by far, the one 
associated with the highest increase in the unadjusted risk of cardiovascular death (Figure 2). 
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Figure 2. Event rates for cardiovascular death. Unadjusted rates (95% CI) per 1000 patient-years for 
cardiovascular death are indicated in the total study population, by category of eGFR, diabetic status, 
systolic blood pressure level, smoking status, previous myocardial infarction, and history of heart 
failure. 
Event rates, and crude and adjusted HRs for all outcomes, for each eGFR category, are reported 
in Table 2. Unadjusted rates of cardiovascular mortality were 6.2, 9.6, 17.8, 32.3, and 70.0 per 1000 
patient-years in patients with eGFR ≥ 90, 60–89, 45–59, 30–44, and <30 mL/min/1.73 m2. Even after 
multiple adjustments for baseline cardiovascular disease, risk factors, comorbidities, and drugs, a 
lower eGFR was associated with increased risk of cardiovascular death, with adjusted HRs (95% CI) 
of 0.98 (0.81–1.18), 1.31 (1.05–1.63), 1.77 (1.38–2.27), and 3.12 (2.25–4.33), for eGFR 60–89, 45–59, 30–
44, and <30 mL/min/1.73 m2, as compared with eGFR ≥ 90 mL/min/1.73 m2. The adjusted risk was 
also significantly increased as early as stage 3a CKD (eGFR 45–59 mL/min/1.73 m2) for all-cause 
death, with adjusted HRs (95% CI) of 0.99 (0.85–1.15), 1.23 (1.03–1.46), 1.72 (1.41–2.10), and 2.96 
(2.27–3.86) for eGFR 60–89, 45–59, 30–44, and <30 mL/min/1.73 m2, as compared with eGFR ≥ 90 
mL/min/1.73 m2, and for admission for heart failure, with adjusted HRs (95% CI) of 1.10 (0.93–1.29), 
1.36 (1.12–1.66), 2.08 (1.65–2.63), and 2.11 (1.44–3.11) for eGFR 60–89, 45–59, 30–44, and <30 
mL/min/1.73 m2, as compared with eGFR ≥ 90 mL/min/1.73 m2. Although crude risk increased as 
eGFR decreased for myocardial infarction and stroke, adjusted HRs were only significantly 
increased for myocardial infarction when eGFR was below 30 mL/min/1.73 m2. 
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Table 2. Event rates and crude and adjusted hazard ratios by GFR subgroups. 
 GFR Subgroups (in mL/min/1.73 m
2) 
 p-Value 
<30 (n = 233) 30–44 (n = 1166) 45–59 (n = 3347) 60–89 (n = 11693) ≥ 90 (n = 5472) 
Cardiovascular death        
number of events 60 159 268 515 156  
event rate (per 1000 P-Y) 70.0 (52.3–87.7) 32.3 (27.3–37.3) 17.8 (15.7–20.0) 9.6 (8.8–10.4) 6.2 (5.2–7.2)  
unadjusted HR 11.63 (8.64–15.67) 5.27 (4.23–6.57) 2.88 (2.37–3.51) 1.55 (1.30–1.86) 1.00 (-) <0.0001 
adjusted HR a 3.12 (2.25–4.33) 1.77 (1.38–2.27) 1.31 (1.05–1.63) 0.98 (0.81–1.18) 1.00 (-) <0.0001 
All-cause death        
number of events 88 246 412 848 243  
event rate (per 1000 P-Y) 102.7 (81.2–124.1) 50.0 (43.7–56.2) 27.4 (24.8–30.0) 15.8 (14.8–16.9) 9.6 (8.4–10.9)  
unadjusted HR 11.02 (8.64–14.07) 5.25 (4.40–6.27) 2.85 (2.43–3.34) 1.64 (1.42–1.89) 1.00 (-) <0.0001 
adjusted HR a 2.96 (2.27–3.86) 1.72 (1.41–2.10) 1.23 (1.03–1.46) 0.99 (0.85–1.15) 1.00 (-) <0.0001 
Myocardial infarction (fatal or not)       
number of events 23 62 149 419 176  
event rate (per 1000 P-Y) 27.7 (16.4–39.0) 12.8 (9.6–16.0) 10.0 (8.4–11.7) 7.9 (7.1–8.7) 7.1 (6.0–8.1)  
unadjusted HR 3.92 (2.54–6.06) 1.80 (1.35–2.41) 1.42 (1.14–1.76) 1.12 (0.94–1.33) 1.00 (-) <0.0001 
adjusted HR a 2.73 (1.72–4.33) 1.29 (0.94–1.77) 1.11 (0.87–1.42) 0.98 (0.81–1.18) 1.00 (-) <0.0001 
Stroke (fatal or not)          
number of events 10 46 110 248 79  
event rate, n/N 11.8 (4.5–19.1) 9.5 (6.7–12.2) 7.4 (6.0–8.8) 4.7 (4.1–5.3) 3.2 (2.5–3.9)  
unadjusted HR 3.78 (1.96–7.31) 3.02 (2.10–4.35) 2.35 (1.76–3.13) 1.48 (1.15–1.91) 1.00 (-) <0.0001 
adjusted HR a 1.47 (0.74–2.93) 1.25 (0.84–1.87) 1.17 (0.85–1.61) 1.00 (0.76–1.30) 1.00 (-) 0.4193 
Hospital admission for heart failure          
number of events 34 148 267 619 211  
event rate (per 1000 P-Y) 43.1 (28.6–57.6) 32.0 (26.8–37.1) 18.5 (16.3–20.7) 11.9 (11.0–12.8) 8.6 (7.4–9.8)  
unadjusted HR 5.06 (3.52–7.27) 3.74 (3.03–4.61) 2.16 (1.80–2.58) 1.39 (1.19–1.62) 1.00 (-) <0.0001 
adjusted HR a 2.11 (1.44–3.11) 2.08 (1.65–2.63) 1.36 (1.12–1.66) 1.10 (0.93–1.29) 1.00 (-) <0.0001 
P-Y = patient-years; HR = hazard ratio; 95% CI=95% confidence interval. a Adjusted for age, sex, 
geographical region, smoking status, diabetes, body-mass index, treated hypertension, baseline 
systolic blood pressure, low-density and high-density lipoprotein cholesterol levels, previous 
myocardial infarction, previous percutaneous coronary intervention, previous coronary artery 
bypass grafting, number of diseased coronary vessels at baseline, peripheral artery disease at 
baseline, previous stroke or transient ischemic attack, previous hospital admission for (or symptoms 
of) heart failure, left ventricular ejection fraction, atrial fibrillation or flutter, and baseline drugs (any 
antiplatelet, statins, angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, and 
beta-blockers). 
When eGFR was analyzed as a continuous variable, worsening of eGFR below 90 mL/min/1.73 
m2 was significantly associated with all outcomes, with adjusted HRs (95% CI) of 1.079 (1.060–1.099), 
1.073 (1.057–1.088), 1.029 (1.005–1.053), 1.033 (1.004–1.063), and 1.061 (1.042–1.080) for cardiovascular 
death, all-cause death, myocardial infarction, stroke, and hospital admission for heart failure, 
respectively (Table 3). 
Table 3. Crude and adjusted hazard ratios per 5 units decrease in eGFR below 90 mL/min/1.73 m2. 
 HR (95% CI) Per 5 Unit Decrease in eGFR (in mL/min/1.73 m2) p-Value 
Cardiovascular death   
unadjusted HR 1.179 (1.161–1.198) <0.0001 
adjusted HR a 1.079 (1.060–1.099) <0.0001 
All-cause death    
unadjusted HR 1.171 (1.157–1.186) <0.0001 
adjusted HR a 1.073 (1.057–1.088) <0.0001 
Myocardial infarction (fatal or not)   
unadjusted HR 1.060 (1.039–1.081) <0.0001 
adjusted HR a 1.029 (1.005–1.053) 0.0154 
Stroke (fatal or not)   
unadjusted HR 1.110 (1.083–1.138) <0.0001 
adjusted HR a 1.033 (1.004–1.063) 0.0273 
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Hopital admission for heart failure   
unadjusted HR 1.124 (1.107–1.142) <0.0001 
adjusted HR a 1.061 (1.042–1.080) <0.0001 
Values above 90 mL/min/1.73 m2 are truncated at this threshold. HR = hazard ratio; 95% CI = 95% 
confidence interval. a Adjusted for age, sex, geographical region, smoking status, diabetes, 
body-mass index, treated hypertension, baseline systolic blood pressure, low-density and 
high-density lipoprotein cholesterol levels, previous myocardial infarction, previous percutaneous 
coronary intervention, previous coronary artery bypass grafting, number of diseased coronary 
vessels at baseline, peripheral artery disease at baseline, previous stroke or transient ischemic attack, 
previous hospital admission for (or symptoms of) heart failure, left ventricular ejection fraction, atrial 
fibrillation or flutter, and baseline drugs (any antiplatelet, statins, angiotensin-converting enzyme 
inhibitors, angiotensin-receptor blockers, and beta-blockers). 
Interaction analyses are presented in eTable in the Supplement. No significant interaction was 
found between CKD and diabetes, treated hypertension, or age when eGFR was analyzed in five 
categories. When eGFR was analyzed as a continuous variable, a significant interaction was 
observed between eGFR and history of hypertension. Indeed, a decreasing eGFR was associated 
with an increased risk of myocardial infarction and with an increased risk of stroke only in patients 
with hypertension (p-values for interaction 0.0090 and 0.0313 for myocardial infarction and stroke, 
respectively).  
4. Discussion 
In this large international contemporary registry of patients with coronary artery disease, a 
reduced eGFR was associated with a gradual increase in the risks of mortality and adverse 
cardiovascular events. This increased risk appeared as early as CKD stage 3a (eGFR 45–59 
mL/min/1.73 m2) for both cardiovascular and total mortality, and persisted after multiple 
adjustments for potential confounding factors, including cardiovascular risk factors, overt 
cardiovascular disease at baseline, comorbidities, and medication. In addition, the large size of the 
cohort allowed us to reliably estimate the risks associated with CKD, compared to those associated 
with diabetes, elevated systolic blood pressure, smoking, and previous myocardial infarction or 
heart failure in patients with coronary artery disease treated in routine practice. CKD stage 3b or 
more, as estimated from the CKD-EPI equation [11,12], was a marker of substantially increased risk 
in patients with coronary artery disease, far higher than that associated with all above-mentioned 
risk factors and conditions. 
In the present analysis, the risk associated with eGFR 60–89 mL/min/1.73 m2 did not differ from 
that associated with eGFR ≥ 90mL/min/1.73 m2. Accordingly, for GFR values of 60 mL/min/1.73 m2 or 
more, the GFR value, per se, does not define CKD in the absence of markers of kidney damage such 
as albuminuria or morphological abnormalities [13]. 
Below 60 mL/min/1.73 m2, prior studies have generally shown an association between a lower 
eGFR and adverse cardiovascular outcomes and mortality [14], although data are not all consistent, 
especially regarding the threshold of eGFR below which risk increases. 
In the REACH registry of patients at very high cardiovascular risk, Dumaine et al. found that 
severe CKD (as estimated by creatinine clearance below 30 mL/min/1.73 m2, hence a true GFR below 
this threshold) was associated in increased risks of mortality, myocardial infarction, and death, 
whereas no significantly increased risk was found above this value [6]. Similarly, several studies 
conducted in community-based cohorts found no significant association between moderate CKD 
and death or cardiovascular disease [15,16]. In contrast, in a meta-analysis of general population 
cohorts, Matsushita et al. found that mortality was unrelated to eGFR above 75 mL/min/1.73 m2, and 
increased below this value [3]. Likewise, in 15,582 subjects from the Atherosclerosis Risk in 
Communities (ARIC) study, an eGFR between 60 and 89 mL/min/1.73 m2 was associated with an 
increased risk of atherosclerotic cardiovascular disease compared with an eGFR of 90 to 150 
mL/min/1.73 m2 [2]. 
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As previously observed in numerous other studies [17], the magnitude of the risk associated 
with a lower eGFR diminished after adjustment, indicating that demographic and clinical 
characteristics of patients with CKD, including older age, higher blood pressure [18], and prior 
cardiovascular disease [19], contribute in part to the association between CKD and risks of death and 
cardiovascular disease. Comorbidities ought to be taken into account when assessing renal and 
cardiovascular risks of patients with CKD [20]. In addition, although overall rates of secondary 
prevention therapies were high in the CLARIFY population, patients with CKD received suboptimal 
treatment [8]. The proportion of patients receiving antiplatelets, lipid-lowering drugs, and 
beta-blockers decreased from 97.8% to 88.8%, 94.4% to 91.4%, and 78.3% to 72.1%, respectively, in 
patients with eGFR ≥ 90 compared with those with eGFR <30 mL/min/1.73 m2. Patients with CKD 
stage 3 received the highest rate of renin-angiotensin system blockers (80.1% for CKD stage 3a and 
79.7% for CKD stage 3b), but this rate decreased to 70.4% in patients with eGFR <30mL/min/1.73 m2. 
In addition to the higher burden of comorbidities [20], suboptimal secondary prevention may 
contribute in part to the higher event rates observed with more advanced CKD [21–23]. 
However, a lower eGFR was still strongly associated with adverse outcomes after adjustment 
for risk factors, baseline cardiovascular disease, comorbidities, and medications. Multiple 
pathophysiological explanations have been proposed in favour of a causal link underlying the 
adverse cardiovascular profile of CKD patients [1,24]. These include increased intravascular calcium 
phosphate deposition and coronary artery calcification, [25–27] arterial stiffness, enhanced 
coagulability, endothelial dysfunction, increased subclinical inflammation, [28] volume overload 
[29], and left ventricular remodeling and dysfunction [30,31]. In addition, patients with CKD 
undergoing percutaneous coronary intervention for an acute coronary syndrome have been shown 
to have less complete revascularization, a condition associated with a poorer prognosis [32]. 
Our results draw attention to the particularly high risk associated with CKD in patients with 
coronary artery disease. Whether or not CKD is a “coronary artery disease risk equivalent” (i.e., the 
risk associated with CKD in patients without coronary artery disease at baseline is equivalent to that 
associated with established coronary artery disease) is debated [17,33], but the present study shows 
that in patients with established chronic coronary artery disease, CKD markedly and 
dose-dependently further increases the risks for total and cardiovascular mortality and 
cardiovascular events. This increased risk is similar to that conferred by diabetes or a systolic blood 
pressure ≥160 mmHg for CKD stage 3a, and much higher than that of any risk factor or comorbid 
condition, including a history of heart failure, for CKD stage 3b or more. These results obtained in 
patients with coronary artery disease are line with those obtained in the general population by 
Tonelli et al., who showed a higher cardiovascular risk in patients with eGFR <60 and even more so 
<45 mL/min/1.73 m2 than in those with diabetes [17]. 
These results strongly support integrating eGFR in risk assessment and treatment targets for 
secondary prevention in patients with coronary artery disease. Patients with eGFR below 60 
mL/min/1.73 m2 need to be monitored carefully and clinicians should attempt to optimize secondary 
prevention throughout follow-up. Prevention of end-stage renal disease is very important, but not 
the only goal in these patients who require effective cardiovascular intervention to reduce the 
exponential cardiovascular burden associated with decreasing eGFR. Patients are more likely to die 
or suffer adverse cardiovascular events than develop end-stage renal disease [12,14]. 
The prevalence of diabetes in our study population was 30%. Interestingly, no interaction was 
found between eGFR and diabetes, for any of the studies outcomes. This is in line with the 
meta-analysis by Fox et al. which showed, in thirty combined general population and high-risk 
cohorts, that the relative increases in risks of total and cardiovascular mortality with lower eGFR 
were the same in patients with and without diabetes [34]. Altogether, this supports the use of similar 
thresholds for diagnosis and classification of CKD in the presence or absence of diabetes. It’s 
noteworthy that patients with both CKD and diabetes, or at high risk for new onset diabetes, are at 
extremely high risk due to the combination of both conditions [35]. 
The analysis of eGFR as a continuous variable revealed a significant interaction between 
worsening renal function and a history of treated hypertension for the outcomes myocardial 
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infarction and stroke (significant effect only in patients with hypertension). However, no interaction 
with hypertension was observed for the other outcomes, including cardiovascular mortality. In 
contrast, in the study by Mahmoodi et al. [4], the relative risk of mortality associated with a lower 
eGFR was stronger in non-hypertensive than hypertensive patients. Overall, the presence of CKD 
should be considered a relevant additional risk factor for cardiovascular mortality, irrespective of 
hypertension and diabetes status. 
Strengths of our study include that patients were recruited from 43 countries, and treated 
according to routine clinical practice, with detailed and source-verified information on risk factors 
and comorbidities as well as outcome identification, and thereby reflect worldwide epidemiology of 
coronary artery disease patients, and are more generalizable than results obtained in the highly 
selected populations from most randomized clinical trials. These data are unique in a contemporary 
cohort of patients with chronic coronary artery disease and provide important data on the risk 
associated with CKD, versus that associated with other risks factors including diabetes, in this 
specific population. In addition, the large sample size allowed adjusting for multiple potential 
confounders, which is very important in the case of CKD patients who suffer multiple comorbidities. 
Our study has several limitations. Due to restrictions preventing collection of ethnicity data in 
some European countries, eGFR based on the CKD-EPI equation was not available in the entire 
CLARIFY population. Another limitation, inherent to the nature of a registry, was that serum 
creatinine concentration measurement was not standardized across centres. In addition, proteinuria 
was not collected in the CLARIFY registry, so we could not analyze the expected even higher risk in 
patients with both CKD and proteinuria [3,5]. 
In conclusion, eGFR <60 mL/min/1/73 m2 was associated with a gradually increasing risk of 
all-cause and cardiovascular mortality, independently of multiple potential confounders. Even 
moderately reduced eGFR should draw at least as much attention as well-recognized risk factors 
and high-risk conditions such as diabetes, uncontrolled hypertension, and previous myocardial 
infarction. These findings are unique in a population with chronic coronary artery disease and 
underscore the high cardiovascular risk associated with CKD, especially of stage 3 or more, 
suggesting the clinical and public health importance of identifying and treating risk factors for 
cardiovascular disease in these patients. 
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